Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining command

Mark S Freedman1, Bruce Cohen, Suhayl Dhib-Jalbut

  • 1University of Ottawa, Smyth Rd., Ottawa, ON, Canada K1H 8L6. mfreedman@ottawahospital.on.ca

Abstract

Insights

Managing multiple sclerosis (MS) that is suboptimally controlled remains challenging due to a lack of evidence-based treatment guidelines. Individualized approaches are needed to optimize therapies for patients with breakthrough disease activity.

Area of Science:

  • Neurology
  • Immunology

Background:

  • Current multiple sclerosis (MS) therapies offer disease reduction but not complete control.
  • Suboptimally controlled MS presents significant challenges in clinical management.

Purpose of the Study:

  • To review definitions and treatments for suboptimally controlled MS.
  • To increase clinician awareness in recognizing and managing these patients.

Main Methods:

  • Literature search of EMBASE and MEDLINE for treatment failure and optimization studies.
  • Inclusion of expert panel discussions on diagnosing and treating suboptimally controlled MS.

Main Results:

  • Recommendations exist for evaluating suboptimal response to disease-modifying drugs (DMDs).
  • Limited evidence-based data guide treatment decisions for suboptimal response.
  • Proposed treatment paradigms include step therapy and platform therapy approaches.

Conclusions:

  • Identifying and treating MS with suboptimal response to platform therapies is challenging without robust data.
  • Developing algorithms to quantify breakthrough disease activity is a key goal.
  • Individualized step therapy and consideration of all factors influencing DMD efficacy are crucial.

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...